Several disease-modifying therapies have recently been approved for relapsing-remitting multiple sclerosis (RRMS), bringing the total to 10 in the United States. Alemtuzumab is an additional option available in Europe and Canada. Treatment selection can be challenging as clinicians attempt to balance efficacy and safety, which is complicated by the paucity of direct comparative data. In the AFFIRM trial, natalizumab reduced annualized relapse rate by 68% and accumulation of new or enlarging T2 lesions by 83%. 1 In comparison, in the FREEDOMS trial, fingolimod reduced annualized relapse rate by 54% and accumulation of new or enlarging T2 lesions by 74%. 2 Although these studies involved different populations and methodologies, many neurologists interpret these results to indicate that natalizumab is more potent than fingolimod and, based on similar cross-trial comparisons, other agents. Despite natalizumab's perceived efficacy advantage, its use is limited by the risk of progressive multifocal leukoencephalopathy (PML). The introduction of John Cunningham virus (JCV) antibody serologic testing allows for PML risk stratification based on prior exposure to the virus. 3 A patient's JCV serologic status is often a key factor in the decision to use natalizumab versus some other agent for patients with breakthrough disease.
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In this issue of Multiple Sclerosis Journal, Carruthers et al. report an observational study comparing the efficacies of natalizumab and fingolimod as secondline therapies in clinical practice. 4 They retrospectively identified 105 RRMS patients who were switched either to natalizumab (n=69) or to fingolimod (n=36) reportedly based on JCV serologic status. Their clinical database was then analyzed for the time to first relapse in these patients, as well as a composite outcome consisting of time to first relapse or presence of a gadolinium-enhanced lesion on magnetic resonance imaging. No differences between the treatment groups were identified in an unadjusted analysis. However, after adjusting for various potential confounders, natalizumab performed significantly better on both outcomes. The hazard of a relapse was 2.61-3.17 times higher for fingolimod patients depending on which possible confounders were included in the model. Further, the hazard of reaching the composite outcome was 2.58-3.17 times higher for fingolimod patients. Thus, the results from Carruthers et al. support superior efficacy of natalizumab compared with fingolimod.
Patients were more likely to discontinue natalizumab (36.2%) than fingolimod (22.2%). This was primarily driven by a somewhat higher than expected JCV seroconversion rate (11.6%) and the development of natalizumab neutralizing antibodies. Of note, the more sensitive second-generation JCV enzyme-linked immunosorbent assay was introduced during the data collection period, suggesting that some of the seroconverters may have been false negatives to begin with. Regardless, the observation that patients started on fingolimod were more likely to remain on the selected treatment than those started on natalizumab may be an important factor to consider for the practicing neurologist.
A useful aspect of Carruthers and colleagues' study is its real-world setting. The broad inclusion criteria allowed any RRMS patient to be analyzed as long as the patient was switched to natalizumab or fingolimod based on JCV serologic status. Information garnered from this type of study has generalizability that may not be available from clinical trials with stringent eligibility criteria, and detailed treatment and monitoring protocols. However, the reader must bear in mind that retrospective observational studies have inherent limitations that necessitate cautious interpretation. One key shortcoming is the potential for indication bias, that is, that in clinical practice patient attributes and other factors, both recognized and latent, contribute to treatment decisions. Thus, the treatment groups in observational studies may not be comparable at baseline. One of the main purposes of randomization in clinical trials is to address that issue. In this study, the authors made use of JCV serologic status to decide whether a patient received natalizumab or fingolimod, based in part on the fortuitous fact that approximately 50% of patients are JCV seropositive. 5 One could argue it would be inappropriate to randomize JCV seropositive patients to natalizumab. Thus, one advantage of using JCV serologic status to determine treatment was that it allowed the inclusion of all patients.
Natalizumab and fingolimod: Insight into their relative efficacies in clinical practice

Devon S Conway and Jeffrey A Cohen
The validity of this approach depends on the assumption that JCV serologic status is independent of MS disease activity, severity, or prognosis. While preliminary data argue against a causative role for JCV in MS, 6 no extant research definitively confirms that JCV infection does not affect disease characteristics or, vice versa, that the presence of MS or its treatment do not affect JCV serologic status. Further, JCV serologic positivity might be associated with behaviors or other characteristics that could influence MS disease course. An alternative approach might have been to analyze exclusively JCV negative patients. A sample of fingolimod and natalizumab patients matched on important clinical characteristics could then have been generated, perhaps using propensity scores. 7 However, this approach would have limited the number of available patients.
An additional concern is the authors' contention that JCV status was the sole deciding factor determining treatment with natalizumab or fingolimod. Treatment selection in MS is complex and many considerations are important, including unpredictable human qualities such as risk tolerance and the likelihood of medication compliance. It is difficult to believe that the patients and clinicians involved in this study had no other conscious or unconscious preferences affecting the treatment decision, which may have introduced indication bias into the comparison. Although no significant differences in individual baseline characteristics were found between the treatment arms, the features in aggregate suggest the fingolimod group had more active disease. A prospective study in which patients were enrolled, provided informed consent, and were explicitly assigned to treatment based on JCV serologic status would have been a stronger design.
Nevertheless, this study provides useful information and introduces an interesting approach to treatment assignment for real-world studies in MS. Although a formal randomized blinded trial would have yielded a more rigorous comparison of natalizumab and fingolimod, it is unlikely that such a trial will be conducted. Hence, we are reliant upon creative observational studies such as the one reported by Carruthers et al.
